Pfizer Anticipates ‘Fair’ Share Of Adalimumab Market In US

Company Expects To Use Interchangeability Designation To Its Advantage

Pfizer expects to make significant strides in the adalimumab market once it launches its Humira biosimilar late next year, but may not be able to enjoy its anticipated interchangeability designation until 2024.

Pfizer logo
Pfizer expects to launch its Humira biosimilar late next year. • Source: Alamy

During the firm’s Q1 results call, Pfizer Inc.’s biopharmaceuticals group president Angela Hwang said that the company expects to gain a “fair” share of the adalimumab market when it launches its biosimilar to AbbVie’s Humira in the US next year.

Pfizer’s approved adalimumab biosimilar, Abrilada (adalimumab-afzb), is anticipated to launch in the US as early as 1 July 2023, under a 2019 agreement with AbbVie

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products